KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$61.5 million.

  • AbCellera Biologics' Free Cash Flow fell 2979.87% to -$61.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.1 million, marking a year-over-year increase of 2242.2%. This contributed to the annual value of -$187.0 million for FY2024, which is 5473.08% down from last year.
  • Latest data reveals that AbCellera Biologics reported Free Cash Flow of -$61.5 million as of Q3 2025, which was down 2979.87% from -$45.8 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Free Cash Flow registered a high of $241.7 million during Q2 2022, and its lowest value of -$139.3 million during Q3 2022.
  • Its 5-year average for Free Cash Flow is -$2.3 million, with a median of -$23.6 million in 2024.
  • The largest annual percentage gain for AbCellera Biologics' Free Cash Flow in the last 5 years was 796198.96% (2021), contrasted with its biggest fall of 1157053.57% (2021).
  • Over the past 5 years, AbCellera Biologics' Free Cash Flow (Quarter) stood at -$26.1 million in 2021, then surged by 171.08% to $18.6 million in 2022, then tumbled by 283.2% to -$34.0 million in 2023, then skyrocketed by 30.59% to -$23.6 million in 2024, then crashed by 160.36% to -$61.5 million in 2025.
  • Its last three reported values are -$61.5 million in Q3 2025, -$45.8 million for Q2 2025, and -$22.2 million during Q1 2025.